Equities

Venture Life Group PLC

VLG:LSE

Venture Life Group PLC

Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (GBX)69.50
  • Today's Change2.00 / 2.96%
  • Shares traded1.18m
  • 1 Year change102.92%
  • Beta0.5714
Data delayed at least 20 minutes, as of Feb 06 2026 10:31 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The Company is focused on product development and commercialization within the global consumer healthcare sector. Its product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, and Gelclair and Pomi-T for oncology support products that provide symptomatic relief for some of the side effects associated with cancer and its treatment. Its products include Baby Earol, EarolSwim, Earol, Glucogel, and Lift Glucose. The products, which are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples and are sold in over 90 countries worldwide. In the United Kingdom and The Netherlands, products are supplied direct by the Company to retailers, elsewhere they are supplied by its international distribution partners.

  • Revenue in GBP (TTM)18.53m
  • Net income in GBP-295.00k
  • Incorporated2005
  • Employees58.00
  • Location
    Venture Life Group PLCUnit 12, The Courtyard, Eastern RoadBRACKNELL RG12 2XBUnited KingdomGBR
  • Phone+44 13 4457 8004Fax+44 13 4474 2970
  • Websitehttps://www.venture-life.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
IND Swift Laboratories Ltd78.91m22.54m81.58m1.25k81.58m1.25k
Curatis Holding AG9.65m-1.56m82.23m15.0082.23m15.00
Karyopharm Therapeutics Inc105.36m-92.12m82.43m279.0082.43m279.00
BRIM Biotechnology Inc68.14k-9.04m82.82m--82.82m--
Venus Remedies Ltd57.28m6.24m82.98m1.30k82.98m1.30k
Biostem Technologies Inc173.83m14.93m83.37m67.0083.37m67.00
Lee's Pharmaceutical Holdings Ltd135.88m9.25m83.55m1.04k83.55m1.04k
Venture Life Group PLC18.53m-295.00k83.77m58.0083.77m58.00
Biosyent Inc22.74m4.65m85.37m0.0085.37m0.00
Nang Kuang Pharmaceutical Co Ltd51.89m6.00m85.99m552.0085.99m552.00
Starpharma Holdings Ltd3.00m-5.11m86.00m50.0086.00m50.00
Data as of Feb 06 2026. Currency figures normalised to Venture Life Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

75.61%Per cent of shares held by top holders
HolderShares% Held
Slater Investments Ltd.as of 18 Aug 202535.85m28.30%
BGF Investment Management Ltd.as of 27 Jun 202511.59m9.15%
River Global Investors LLPas of 30 Jun 202510.33m8.15%
Hargreaves Lansdown Asset Management Ltd.as of 31 Dec 20249.15m7.22%
TrinityBridge Ltd.as of 03 Nov 20258.85m6.99%
Stonehage Fleming Investment Management Ltd.as of 30 Jun 20258.42m6.65%
Chelverton Asset Management Ltd.as of 31 Dec 20244.36m3.45%
Harwood Capital LLPas of 15 Dec 20253.75m2.96%
Hargreaves Lansdown Fund Managers Ltd.as of 03 Nov 20252.17m1.71%
Quilter Cheviot Ltd.as of 03 Nov 20251.31m1.04%
More ▼
Data from 31 Mar 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.